ICER Will Assess Real World Evidence On Accelerated Approvals After Two Years
Executive Summary
Process will incorporate real world evidence into future cost effectiveness updates of already reviewed drugs to supplement the information available prior to launch.
You may also be interested in...
ICER Partnering With Aetion To Scale Up Use Of RWE In Value Assessments
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
ICER’s Biopharma Members: Why They Joined And What They Get
Biopharma’s funding support for the Institute for Clinical and Economic Review has been slightly above that of payers and providers for the past three to four years.
Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
